IBRX News and Press, ImmunityBio Inc. From 09/11/23

2023-09-11 06:26:56 ET ImmunityBio ( NASDAQ: IBRX ) Monday said it has executed financing transactions resulting in about $200 million of proceeds to the company. The transaction includes an exchange into equity of current debt and a new convertible debt instrument from Nant C...

Financing improves the company’s balance sheet and provides $200 million of capital, as follows: Exchange of $270 million of debt held by Nant Entities into ImmunityBio equity resulting in deleveraging of the Company’s balance sheet $200 million of a new 3-year term debt fin...

2023-08-09 16:26:20 ET Summary ImmunityBio is facing financial and regulatory challenges, resulting in a 50%+ stock drop after an FDA Complete Response Letter. The company's financial situation shows high cash burn and dilution, despite recent fundraising. The updated investme...

NEW YORK, NY / ACCESSWIRE / August 9, 2023 / Levi & Korsinsky, LLP notifies investors in ImmunityBio, Inc. ("ImmunityBio" or the "Company") (NASDAQ:IBRX) of a class action securities lawsuit. The lawsuit on behalf of ImmunityBio investors has been commenced in the United States District C...

2023-08-03 09:07:09 ET ImmunityBio Inc ( NASDAQ: IBRX ) on Thursday named Enrique Diloné to the newly created role of Chief Technology Officer. Diloné will assume responsibility for all global manufacturing functions as the company prepares for potential FDA app...

Veteran manufacturing and supply chain expert to oversee global manufacturing and QA ImmunityBio, Inc. ( NASDAQ: IBRX ), a clinical-stage immunotherapy company, today announced that it has named Enrique Diloné, Ph.D., to the newly created role of Chief Technology Officer. With ...

ImmunityBio, Inc. ( NASDAQ: IBRX ), a clinical-stage immunotherapy company, today announced that it has executed financing to provide further working capital and support its ongoing business operations. The Company entered into a securities purchase agreement for a registered direct offering ...

2023-07-19 12:57:45 ET Shares of ImmunityBio (NASDAQ: IBRX) were up 10% at 11:40 a.m. ET on Wednesday. The clinical-stage biotech company focuses on cell therapies and immunotherapy platforms, including vaccines and therapies to treat infections and cancers. The stock is down than 3...

2023-07-14 17:29:54 ET Gainers: BridgeBio Pharma ( NASDAQ: BBIO ) +15% . Greenidge Generation  ( GREE ) +5% . Conduent  ( CNDT ) +3% . The RealReal ( REAL ) +3% . Quantum-Si  ( QSI ) +3% . Losers: Ebix ...

ImmunityBio, Inc. (NASDAQ: IBRX ), a clinical-stage immunotherapy company, today announced findings from a Phase 1 study showing that allogeneic cytokine-induced memory-like (CIML) natural killer (NK) cells used in combination with ImmunityBio’s IL-15 superagonist N-803 may induce tumo...